| Autor: |
Hasche, G., Stecher, J., Gmelin, K., Doerr, H. |
| Zdroj: |
European Journal of Clinical Microbiology & Infectious Diseases; Feb1984, Vol. 3 Issue 1, p30-34, 5p |
| Abstrakt: |
The antigenic activity of HBcAg produced in Eschericha coli and HBcAg from human liver was compared in a μ-specific solid-phase antibody-capture assay for detection of anti-HBc-IgM. HBcAg from liver could be detected in dilutions up to 1∶3, HBcAg from Escherichia coli in dilutions up to 1∶10, 000. Using HBcAg from Eschericha coli, sera from five patients with acute resolving hepatitis B and sera from four patients with actue hepatitis B who had developed chronic liver disease were tested for anti-HBc-IgM in ELISA. IgM fractions separated out of the same sera by immunoaffinity chromatography were tested for anti-HBc-IgM using a commercially available test. The results were in good agreement with those obtained by ELISA. Anti-HBc-IgM could be detected up to 900 days after onset of disease. Different groups of patients were tested for presence of anti-HBc-IgM in ELISA. Fifty-nine of 60 patients with acute hepatitis B were positive for anti-HBc-IgM at onset of illness. Ten of 16 patients with chronic aggressive hepatitis and seven of 23 HBsAg positive dialysis patients were also positive for anti-HBc-IgM, whereas only two of 12 patients with chronic persistent hepatitis and one of 15 HBsAg positive blood donors ('healthy' carriers of HBsAg) had detectable anti-HBc-IgM. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink